Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of Alagille Syndrome~2. Evidence of cholestasis~3. Moderate to severe pruritus~4. Ability to understand and willingness to sign informed consent/assent prior to initiation of any study procedures~Exclusion Criteria:~1. Surgical disruption of the enterohepatic circulation~2. Liver transplant~3. History or presence of other concomitant liver disease~4. Females who are pregnant or lactating~5. Known HIV infection

- Gender: ALL
- Minimum Age: 12 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- LUM001 (Type: EXPERIMENTAL): LUM001 for oral administration
- Placebo (Type: PLACEBO_COMPARATOR): Placebo administered orally once each day

Based on this trial design, predict the completion outcome and termination type (if applicable).